ALK: Obtained the drug registration certificate for Levofloxacin Tablets
ALK announced that it recently received the "Drug Registration Certificate" for Levofloxacin Tablets issued by the National Medical Products Administration. Levofloxacin Tablets are a third-generation fluoroquinolone antibacterial drug, characterized by a broad antibacterial spectrum and strong antibacterial effects, used to treat mild, moderate, and severe infections in adults caused by specified sensitive strains. The company received the notice of acceptance for the drug marketing authorization application in April 2024 and has recently been approved
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments